- Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026

ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.

Along with a clinical program overview, the event will feature perspectives from REGENXBIO management and leading retina specialists on the treatment landscape, unmet need, ATMOSPHERE® and ASCENT® pivotal trials, and commercial readiness of sura-vec in wet AMD.

Featured key opinion leaders include:

- Gaurav Shah, M.D., FASRS, California Pacific Medical Center, Sutter Health

- Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates

- Lejla Vajzovic, M.D., FASRS, Duke University School of Medicine

- Rahul Khurana, M.D., FASRS, Northern California Retina Vitreous Associates, University of California at San Francisco

- Ramanath Bhandari, M.D., FASRS, Springfield Clinic Eye Institute

Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives

Date: Tuesday, October 20, 2026

Time: 1:00 p.m. ET – 4:00 p.m. ET

Location: New York, NY and Virtual

Registration for the webcast is available at this LINK.   

An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the event.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack

Corporate Communications

[email protected] 

Investors:

George E. MacDougall

Investor Relations

[email protected] 

SOURCE REGENXBIO Inc.

Share this article

DUBLIN, Oct. 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the American College of Gastroenterology Annual Meeting, taking place October 9-14, 2026.

"We are pleased to share these findings with the medical community because they contribute to our understanding of this challenging and rapidly progressive condition," said Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center and presenting author. "The exploratory analysis expands the clinical evidence on the use of terlipressin in liver transplant–ineligible patients and can help providers support those affected by HRS-AKI."

TERLIVAZ is the first and only FDA‑approved therapy indicated to improve kidney function in adults with HRS‑AKI.

Presentation Details

- Date: October 12

- Title: Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial

- Authors: Nancy Reau, MD; Kavish Patidar, DO; Laurie Larson, MSN, APRN; HoChong Gilles, DNP, APRN; R. Todd Frederick, MD; Kevin Regner, MD, MS; Anooj Shah, PharmD, MBA; Richard Wu, PhD; Christopher White, MD, MSPH; Nneka N. Ufere, MD, MSCE

About Hepatorenal Syndrome-Acute Kidney Injury

Hepatorenal syndrome–acute kidney injury (HRS-AKI) is a life-threatening condition in adults with advanced liver disease that is marked by a rapid decline in kidney function1 and is associated with high morbidity and mortality.2 It is an acute medical emergency that requires hospitalization.3 A U.S. study based on national data revealed that the estimated annual number of inpatients diagnosed with HRS between 2018 and 2023 increased from 42,930 to 63,381.4

INDICATION

TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

LIMITATION OF USE

- Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE

- TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO2) before initiating TERLIVAZ. 

- Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO2 90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO2 decreases below 90%.

Contraindications

TERLIVAZ is contraindicated:

- In patients experiencing hypoxia or worsening respiratory symptoms.

- In patients with ongoing coronary, peripheral, or mesenteric ischemia.

Warnings and Precautions

- Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients. Monitor patients for changes in respiratory status using continuous pulse oximetry and regular clinical assessments. Discontinue TERLIVAZ in patients experiencing hypoxia or increased respiratory symptoms.

Manage intravascular volume overload by reducing or discontinuing the administration of albumin and/or other fluids and through judicious use of diuretics. Temporarily interrupt, reduce, or discontinue TERLIVAZ treatment until patient volume status improves. Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure.

- Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed. For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.

- Ischemic Events: TERLIVAZ may cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia. Avoid use of TERLIVAZ in patients with a history of severe cardiovascular conditions or cerebrovascular or ischemic disease. Discontinue TERLIVAZ in patients who experience signs or symptoms suggestive of ischemic adverse reactions.

- Embryo-Fetal Toxicity: TERLIVAZ may cause fetal harm when administered to a pregnant woman. If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus.

Adverse Reactions

- The most common adverse reactions (≥10%) include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

Please click here to see full Prescribing Information, including BOXED WARNING.

About Keenova

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit www.keenova.com.

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations, and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Information Regarding Forward-Looking Statements

This release contains forward-looking statements, including with regard to TERLIVAZ®, the efficacy, safety, potential treatments or indications, therapeutic outcomes or treatment responses of this product, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with TERLIVAZ; and other risks identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Keenova's most recent Annual Report on Form 10-K, and other filings and furnishings with the Securities and Exchange Commission (SEC), all of which are available on the SEC's website (www.SEC.gov) and Keenova's website (www.keenova.com). The forward-looking statements made herein speak only as of the date hereof and Keenova does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

References

- Wong RJ, Balasubramanian J, Panaccio M, Huang X. Acute kidney injury and hepatorenal syndrome among hospitalized patients with chronic liver disease. JAMA Netw Open. 2025;8(5):e2511816.

- Loftus M, Brown RS Jr, El-Farra NS, Owen EJ, Reau N, Wadei HM, Bernstein D. Improving the management of hepatorenal syndrome–acute kidney injury using an updated guidance and a new treatment paradigm. Gastroenterol Hepatol (N Y). 2023;19(9):527-536.

- National Organization for Rare Disorders. Hepatorenal syndrome. Available at https://rarediseases.org/rare-diseases/hepatorenal-syndrome. Accessed March 17, 2026.

- Goyes M, et al. Increasing incidence, cost, and mortality of AKI and HRS in hospitalized patients with cirrhosis. JAMA Netw Open. 2025;8(5):e2511822.

SOURCE Keenova Therapeutics

Share this article

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.

The study, "Development and Implementation of a Cirrhosis Clinical Pathway: Outcomes of a 6-Month Pilot Study," assessed the feasibility and impact of a multidisciplinary clinical pathway designed to reduce variability in cirrhosis care and improve adherence to guideline-recommended management practices.

Cirrhosis is associated with significant morbidity and healthcare utilization, yet management approaches often vary across clinical settings. To address this challenge, investigators developed a standardized pathway informed by current clinical guidelines and evidence-based practices, with contributions from both academic and community-based healthcare providers.

The pathway was implemented across five community gastroenterology practices as part of a six-month quality improvement initiative. Using population health analytics, investigators monitored adherence to five key performance indicators, including follow-up office visit, laboratory testing, nonselective beta-blocker use in patients with varices, hepatic encephalopathy treatment, and enrollment in chronic care management programs.

The analysis included 4,251 patients with cirrhosis and demonstrated measurable improvements across several care metrics during the six-month pilot period:

- Office visit adherence increased from 46.9% at baseline to 51.1%, representing a 9.0% relative improvement.

- Recommended laboratory monitoring adherence increased from 61.5% to 63.5%, a 3.2% relative improvement.

- Non-selective beta-blocker treatment rates among patients with varices increased from 47.2% to 48.8%, a 3.4% relative improvement.

- Medication treatment rates for reducing hepatic encephalopathy recurrence increased from 60.2% to 64.9%, a 7.8% relative improvement.

- Enrollment in chronic care management/principal care management programs increased from 11.7% to 12.8%, representing a 9.4% relative improvement.

The investigators concluded that implementation of a standardized cirrhosis clinical pathway, supported by population health analytics, was feasible in community practice and resulted in improved adherence to guideline-based monitoring and treatment recommendations.

"These results highlight the value of a clinical pathway in helping providers deliver more consistent, guideline-based care for patients with cirrhosis," said Peng-Sheng (Brian) Ting, MD, principal investigator of the pilot initiative. "As the burden of liver disease continues to grow, broader adoption of proven care pathways may help close gaps in care, improve treatment adherence, and support better patient outcomes."

About the Study

The study leveraged the Cardinal Health PPS Analytics platform to identify gaps in care and monitor adherence to predefined clinical pathway benchmarks. Investigators believe the approach may serve as a scalable model for improving cirrhosis management in community practice settings and supporting delivery of guideline-concordant care.

The data presented in this release reflect findings submitted to and accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting & Postgraduate Course 2026. Findings should be considered preliminary until presented and further evaluated in peer-reviewed publications.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

©2026 Salix Pharmaceuticals or its affiliates.

SOURCE Bausch Health Companies Inc.

Share this article

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management.

For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows. While advances in medical science have significantly improved diagnosis and treatment, the fundamental model has remained largely reactive.

Today, advances in AI, healthcare data and remote monitoring technologies are beginning to reshape this model. Wearable devices and remote patient monitoring ("RPM") technologies can support continuous collection of health indicators outside traditional clinical settings, while longitudinal and real-world healthcare data can provide a broader view of changes in an individual's health status. AI can help analyze these multidimensional datasets, identify potential risk signals and support more timely healthcare decisions.

Pomdoctor believes the convergence of these technologies is enabling healthcare to evolve from "diagnose and treat" toward "predict, alert and intervene," with particular relevance to chronic disease management, where continuous monitoring and timely intervention can play an important role in long-term health management.

Pomdoctor's Role in the Transition to Predictive Healthcare

Against this backdrop, Pomdoctor is positioning its healthcare ecosystem to participate in the transition toward predictive healthcare. The Company's strategy combines its existing healthcare operations and physician resources with AI, wearable technologies, RPM capabilities and real-world healthcare data.

Rather than developing these capabilities independently, Pomdoctor aims to integrate them into a coordinated healthcare management framework in which data generated through monitoring and healthcare interactions can support AI-driven analysis, physician follow-up and more personalized health management.

The Company believes its existing healthcare infrastructure and growing technology capabilities provide a foundation to support a more continuous, data-driven and proactive model of care.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented, "For generations, healthcare has largely focused on treating patients after illness or symptoms appear. New technologies are creating the opportunity to move healthcare intervention further upstream. We believe predictive healthcare will become an increasingly important part of future health management. By combining our healthcare operations, physician resources, real-world data and technology capabilities, we aim to help build the infrastructure needed to support this transition."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company's strategy to participate in the transition of healthcare from a reactive model toward a predictive and proactive model; the Company's plans to integrate AI, wearable technologies, remote patient monitoring ("RPM") capabilities and real-world healthcare data with its existing healthcare operations and physician resources into a coordinated healthcare management framework; the Company's pursuit of the development of a predictive healthcare data and services infrastructure; the Company's belief that its existing healthcare infrastructure and technology capabilities provide a foundation for a more continuous, data-driven and proactive model of care; expectations regarding the future role of predictive healthcare, including in chronic disease management; and the anticipated benefits of the Company's strategy for patients, healthcare providers and other ecosystem participants, including improved healthcare outcomes and long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "aims," "estimates," "projects," "intends," "plans," "pursues," "positions," "will," "would," "should," "could," "may" or other similar expressions. These forward-looking statements are based on the Company's current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled "Item 3. Key Information—D. Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2026, and the Company's other filings with the SEC, which are available on the SEC's website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED

Investor Relations Department

Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: [email protected]

SOURCE POMDOCTOR LIMITED

Share this article

The 2026 Ivory Prize Summit to Spotlight Housing Solutions Communities Can Put to Work

National gathering at Arizona State University on Oct. 14 connects housing innovators, policymakers and developers to share knowledge and advance affordability

TEMPE, Ariz., Oct. 12, 2026 /PRNewswire/ -- As the housing affordability crisis continues to grip communities nationwide, Ivory Innovations is bringing the nation's top housing changemakers together to turn bold ideas into real-world action.

Ivory Innovations, an operating foundation and academic center based at the University of Utah, is hosting its annual Ivory Prize Summit on Oct. 14 at Arizona State University. The gathering aims to advance housing affordability by connecting promising innovations with the people and organizations positioned to put them into practice.

The summit fosters collaboration across sectors that too often address housing challenges separately. Its focus on systemic solutions will give attendees an opportunity to exchange ideas and build relationships across policy, development, research, and entrepreneurship.

"The most important thing that we can focus on as we seek to solve the broader issue of housing affordability is taking solutions that already exist and share them with the communities that need them the most." said Abby Ivory, co-founder and president of Ivory Innovations. "We're excited to be bringing industry experts and housing advocates together to share and discuss solutions to a problem that has such a huge impact on families across the country."

Featured presenters:

- Clark Ivory, Ivory Homes CEO and Ivory Innovations Co-founder

- Chris Herbert, Managing Director of Harvard's Joint Center for Housing Studies and Ivory Innovations Advisory Board Chairman

- Eric Kronberg, Principal at Kronberg Urbanists + Architects and Co-founder of Inc Codes

- Laurie Goodman, The Urban Institute's Housing Finance Policy Center Founder

- Jonathan Lawless, Bilt Rewards Head of Homeownership

- Dennis Steigerwalt, Housing Innovation Alliance President

- Alison Cook-Davis, Research Director at Arizona State University's Morrison Institute for Public Policy and Co-Director of the Arizona Research Center for Housing Equity and Sustainability

- Flavio Bravo, Arizona State Senator

- Shawnna Bolick, Arizona State Senator

- Nicole Newhouse, Director of the Arizona Housing Coalition

- Anakaren Lemus, Chief of Government Affairs for the Arizona Department of Housing

The summit will also honor the winners of the 2026 Ivory Prize for Housing Affordability, whose work illustrates how communities can approach affordability in three categories; Construction & Design, Finance, and Policy & Regulatory Reform. This year's winners are TradesFutures, the City of Boston's Boston Acquisition Fund, and the City of Chattanooga's Affordable Housing PILOT and the City of New Rochelle's Downtown Development initiative as co-winners.

These honorees created concrete starting points for a national conversation about housing solutions: preparing more people for construction careers, financing housing acquisition, and using local policy to support affordability and development.

The summit will also include presentations from the three teams that won Hack-A-House, an annual Ivory Innovations competition where college students nationwide propose innovative solutions to housing affordability. These presentations will be livestreamed, followed by a round of voting for the competition's Grand Prize.

The Ivory Prize Summit is presented in partnership with MOD X, Housing Innovation Alliance, the Arizona Research Center for Housing and Economic Solutions, and the Morrison Institute for Public Policy at Arizona State University.

Attendance and media information

The summit will take place Oct. 14, 2026, at Memorial Union, Arizona State University, 301 E. Orange St., Tempe. Registration, parking, and event information are available at ivoryinnovations.org/ivory-prize-summit.

Reporters interested in attending, covering the summit or requesting interviews should contact Ivory Innovations Director of Marketing Anna Burleson at [email protected].

About Ivory Innovations

Ivory Innovations is an operating foundation and academic center based at the University of Utah David Eccles School of Business. Through programs including Hack-A-House, it supports innovative approaches to addressing housing affordability. For more information visit ivoryinnovations.org.

SOURCE Ivory Innovations

Share this article

VUSSENS Establishes U.S. Headquarters in New Jersey and Launches AI-Powered Global Beauty Analytics Platform

Establishing a Strategic Foothold in North America, the World's Largest Beauty Market, to Accelerate Expansion Across Global Brands, Manufacturers, and Retailers

FORT LEE, N.J. and SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- VUSSENS Inc., a global beauty AI analytics company and a wholly owned subsidiary of NEWEN AI, a specialist in industry-specific AI analytics solutions, has established its North American operations in New Jersey and officially launched VUSSENS, its ontology-based AI beauty analytics platform.

New Jersey, where the North American subsidiary is based, is strategically located adjacent to New York, a major global hub for international business and consumer goods distribution, offering strong infrastructure and accessibility. VUSSENS plans to further strengthen its localization strategy in the North American market by actively leveraging its local partnership network, including connections with New York University (NYU) Stern and the Global AI Frontier Lab based in New York.

The VUSSENS platform, officially unveiled alongside the establishment of the North American subsidiary, is a beauty-specialized, ontology-based AI platform that integrates and analyzes cross-channel data from social media and e-commerce platforms in the U.S. market. Powered by a language model trained on more than 800 billion tokens and a multimodal AI engine capable of simultaneously analyzing video, audio, and subtitles across short-form content platforms such as YouTube and TikTok, VUSSENS enables highly granular persona analysis based on race, age, skin type, and consumer values. Going beyond simple measurements of keyword mentions, the platform structurally maps complex relationships such as trends and sales, ingredients and efficacy, and consumer responses and products, providing actionable market insights for businesses in the local market.

The platform integrates four core solutions, Marketing, Trend, Product, and Category, to support practical business decision-making. The Marketing Solution tracks the entire journey from product seeding and content engagement to reviews and purchase-conversion signals, while the Trend Solution captures diverse consumer responses in real time across ingredients, efficacy, formulations, colors, memes, and other dimensions. In addition, the Product Solution supports customized strategy development through AI-powered SWOT analysis and target-consumer analysis, while the Category Solution provides an overview of market movements and category-level opportunities. The platform also features K-Beauty trend analysis, which is gaining attention as a key benchmark in the global beauty market, further strengthening VUSSENS' competitive edge.

VUSSENS plans to pursue an aggressive sales strategy targeting the entire beauty value chain in North America. Its target customers include beauty brands seeking trend intelligence and marketing performance measurement, OEM and ODM manufacturers looking to optimize new product development and ingredient R&D, major retailers seeking to identify promising brands at an early stage, and agencies requiring sophisticated, data-driven insights for strategic proposals and solutions.

VUSSENS has also outlined a concrete roadmap for business expansion. Starting with its New Jersey subsidiary, the company plans to secure its initial customer base and gradually expand its sales hubs across key regions in the U.S., including the West Coast, South, and Midwest, ultimately building a sales network spanning North America. Building on its success in the North American market, VUSSENS plans to gradually expand its services into other major global beauty markets, including Japan, Europe, Southeast Asia, and the Middle East, with the goal of establishing itself as a global beauty data hub.

*NEWEN AI(KOSDAQ, 463020)

About VUSSENS

VUSSENS is an AI-powered global beauty analytics platform that integrates and analyzes global e-commerce and social media data to identify beauty market trends, consumer demand, and changes across products and categories. By integrating major commerce and social data sources, VUSSENS delivers actionable insights across the entire beauty intelligence ecosystem, from Trends →Categories → Products → Marketing. One of VUSSENS' key strengths lies in its ability to connect data across otherwise fragmented channels, enabling businesses to identify emerging beauty trends and early consumer interest signals, while uncovering high-growth categories and product opportunities.

For more information about VUSSENS, please visit the official website: https://vussens.ai

Product Inquiry[email protected]

SOURCE NEWEN AI

Share this article

New soft armor innovation combines proven Kevlar® XP technology with Kevlar® EXO™ fiber to enable next-generation body armor designs with enhanced comfort, mobility, and durability

ALPHARETTA, Ga., Oct. 12, 2026 /PRNewswire/ -- Arclin, a leading materials science company, today announced the launch of Kevlar® EXO™ XP E480, the latest innovation in its personal protection portfolio.

Combining the proven ballistic and trauma-reduction performance of Kevlar® XP technology with the advanced capabilities of Kevlar® EXO™ fiber, the new solution enables body armor manufacturers to achieve significantly lighter weight while meeting NIJ Level IIIA/HG2 protection requirements, helping improve wearer comfort, mobility, and operational effectiveness.

"Protective equipment is only effective if users can wear it comfortably throughout their entire mission," said Joe Hovanec, Arclin's Vice President of Kevlar® EXO™. "With Kevlar® EXO™ XP E480, manufacturers can achieve armor that is up to 25% lighter and provides up to 40% greater comfort*, helping reduce fatigue while maintaining the trusted protection users depend on."

Engineered to perform in demanding field conditions, Kevlar® EXO™ XP E480 combines high stopping power, excellent bullet-flattening performance, and exceptional durability in a lighter-weight construction. The material's unique fiber architecture also helps reduce layer counts and stitching requirements, enabling streamlined armor designs and potentially lowering manufacturing complexity and labor costs.

Kevlar® EXO™ XP E480 is now available for evaluation to customers worldwide. To learn more, visit XPE480 - Arclin.

About Arclin

Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products, and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design, and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities across North & South America, Europe, and Asia and serves customers worldwide. For more information, visit www.arclin.com.

Arclin Media Contact

Jana Wright

Chief Marketing & Communications Officer

[email protected]

*vs. XP K520 for level IIIA/HG2 NIJ.

Kevlar® and Kevlar® EXO™ are registered trademarks of Arclin.

SOURCE Arclin

Share this article

VANCOUVER, BC, Oct. 12, 2026 /PRNewswire/ -- Energy Metal News News Commentary - The long-term uranium price ended September at $96.50 per pound, above the $95 peak reached in 2007, while the spot price closed the month at $89.63, according to figures published by Cameco. The prices that utilities agree to pay years in advance are now running ahead of the spot market, a sign that buyers are planning for tighter supply later in the decade. Producers, developers and lithium suppliers spent the past two weeks reporting results, signing offtake agreements and reorganizing their portfolios. Active Companies from around the markets with current developments this week include: Cameco Corporation (NYSE: CCJ), Uranium Energy Corp. (NYSE American: UEC), enCore Energy Corp. (NASDAQ: EU), Elevra Lithium Limited (NASDAQ: ELVR), National Energy Services Reunited Corp. (NASDAQ: NESR).

Uranium equities have not followed contract prices higher. As of early October, Cameco shares were down 6.9% for the year and 11.6% over the prior month, and the VanEck Uranium and Nuclear ETF (NLR) was down 16.4% year to date, according to Yahoo Finance. Market observers have pointed to utilities' slow pace of new term contracting as one reason the record contract price has not yet translated into share price gains.

Policy support for new reactors continued to build. On September 30, the United States and the Republic of Korea announced a framework anticipating about US$120 billion of Korean investment to help deploy Westinghouse reactor technology in the United States, covering up to six AP1000 units and up to two APR1400 units. The terms are non-binding and subject to final negotiations, definitive agreements, site identification, regulatory approvals and financing.

In lithium, Chinese battery-grade lithium carbonate averaged 122,350 yuan per tonne on October 9, according to Shanghai Metals Market, as buyers returned cautiously after the National Day holiday. Producers outside China continued to secure long-term buyers and new extraction projects.

CONTINUED... Read the weekly sector breakdown in The Roadmap at: stockpreachers.com

In other industry developments and happenings in the market this week include:

Cameco Corporation (NYSE: CCJ)

Cameco, which holds a 49% interest in Westinghouse, acknowledged the U.S.-Korea framework on September 30. Westinghouse is expected to receive about US$2 billion in value per APR1400 unit through intellectual property licensing, engineering and procurement services, subcontracting and long-term fuel fabrication supply. The framework also contemplates a potential Korean equity investment in Westinghouse, which Cameco does not expect to change its ownership interest.

"Cameco remains focused on supporting the US government's objective of quadrupling US civil nuclear capacity by 2050," said Tim Gitzel, CEO of Cameco.

Uranium Energy Corp. (NYSE American: UEC)

Uranium Energy reported fiscal 2026 production of 229,294 pounds of uranium for the year ended July 31, and sold 400,000 pounds from inventory at a weighted average realized price of $93.13 per pound for revenue of $37.3 million. The company held $753 million in liquid assets, including $495 million in cash, with no debt, and 1,256,000 pounds of U3O8 in inventory.

"In fiscal 2026, UEC became a multi-mine uranium producer," said Amir Adnani, President and CEO. "We enter fiscal 2027 debt-free with an exceptional balance sheet and the ability to fund our ongoing growth."

enCore Energy Corp. (NASDAQ: EU)

enCore completed the distribution of 35,000,000 common shares of Verdera Energy Corp., which holds its New Mexico in-situ recovery uranium assets, to enCore shareholders as a special dividend on September 30. enCore retains about 15 million Verdera shares and is now focused on its South Texas operations, its South Dakota project and its U.S. project pipeline.

"Completing the Verdera distribution delivers on our commitment to put value directly in the hands of enCore shareholders," said Rich Little, Chief Executive Officer of enCore.

Elevra Lithium Limited (NASDAQ: ELVR)

Elevra signed a binding offtake agreement with LG Energy Solution on October 7 for 240,000 dry metric tonnes of spodumene concentrate over four years from its operating North American Lithium project in Quebec, with supply beginning later this year. Elevra CEO and Managing Director Lucas Dow described LG Energy Solution as 'a committed customer for a meaningful portion of NAL's production'.

National Energy Services Reunited Corp. (NASDAQ: NESR)

NESR signed an agreement with Saudi Aramco on October 8 to deliver the Aramco 2027 Lithium Demonstration Project, described as the region's first direct lithium extraction project. The project is designed to produce 2,000 tonnes per year of battery-grade lithium carbonate using NESR's LiThara platform, with commissioning planned for late 2027. The contract runs up to five years with a value of approximately US$200 million.

Follow the Metals That Power the Grid

The Roadmap from Stock Preachers is an in-depth market report published every Monday, Wednesday and Friday, tracking the sectors, commodities and companies moving the market each week. Access is free during the public beta at stockpreachers.com.

Contact Information:

energymetalnews.com

Media Contact: [email protected] 

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. It is neither an offer nor a recommendation to buy or sell any security.

This article is being distributed by Energy Metal News, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution, and MEL has no advertising or digital media agreement with any company mentioned in this article. The companies mentioned have not reviewed or approved this article.

Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice.

Information in this article was obtained from sources believed to be reliable, including company news releases, published commodity price data and public market reporting, but its accuracy cannot be guaranteed. Investing in securities involves risk, including the possible loss of some or all of your investment.

References to the companies named in this article are provided solely as market and sector context and as summaries of each company's own public news releases. No partnership, affiliation, or endorsement is implied, and nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to company executives are reproduced from those companies' own news releases. Uranium and lithium prices cited are third-party published figures and may differ from prices realized by any company. The U.S.-Korea framework described is non-binding and subject to final negotiations and approvals. Mining and mineral processing involve significant operational, regulatory and commodity price risks.

Stock Preachers Disclosure. Stock Preachers, including its market report The Roadmap, is a market-commentary publication owned by MEL, and references to it in this article constitute promotion of an affiliated product. Stock Preachers is not a broker-dealer, and nothing on its website, in The Roadmap or in this article is financial, investment, tax, or legal advice. Its content is for informational and educational purposes only. Always do your own research before making any investment decision.

Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company's filings with the SEC.

SOURCE Energy Metal News

Share this article

HELLERUP, Denmark, Oct. 12, 2026 /PRNewswire/ -- TORM plc (NASDAQ: TRMD) (NASDAQ: TRMD A) today announces that, based on the Company's current coverage and expectations for continued market strength during the remainder of the fourth quarter of 2026, TORM has increased its full-year guidance for 2026.

TORM now expects full-year 2026 TCE to be in the range of USD 1,700 – 1,900m and full-year 2026 EBITDA to be in the range of USD 1,300 – 1,500m, compared to previous guidance of TCE of USD 1,400 – 1,600m and EBITDA of USD 1,000 – 1,200m.

"Exceptional market strength and strong execution have led us to raise our full-year guidance to new record levels. Our scale and agility support our track record of market-leading performance," said Jacob Meldgaard, CEO of TORM.

The guidance upgrade reflects stronger-than-previously-anticipated earnings visibility, supported by TORM's current forward freight coverage and continued favorable market conditions across the product tanker market.

TORM expects to publish its third quarter 2026 financial results on 4 November 2026, providing an update on market developments, commercial performance and earnings for the period.

Contact

Mikael Bo Larsen, Head of Investor Relations

Tel.: +45 5143 8002

About TORM

TORM is one of the world's leading carriers of refined oil products. TORM operates a fleet of product tanker vessels with a strong commitment to safety. environmental responsibility and customer service. TORM was founded in 1889 and conducts business worldwide. TORM's shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (NASDAQ: TRMD A) (NASDAQ: TRMD) (ISIN: GB00BZ3CNK81) . For further information, please visit www.torm.com.

Safe Harbor Statement as to the Future

Matters discussed in this release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, "expects," "anticipates," "intends," "plans," "believes," "estimates," "targets," "projects," "forecasts," "potential," "continue," "possible," "likely," "may," "could," "should" and similar expressions or phrases may identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are, in turn, based upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs, or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, our future operating or financial results; changes in governmental rules and regulations or actions taken by regulatory authorities; inflationary pressure and central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates; general domestic and international political conditions or events, including "trade wars" and the war between Russia and Ukraine, the developments in the Middle East, including the war in Israel and the Gaza Strip, and the conflict regarding the Houthis' attacks in the Red Sea; international sanctions against Russian oil and oil products; changes in economic and competitive conditions affecting our business, including market fluctuations in charter rates and charterers' abilities to perform under existing time charters; changes in the supply and demand for vessels comparable to ours and the number of newbuildings under construction; the highly cyclical nature of the industry that we operate in; the loss of a large customer or significant business relationship; changes in worldwide oil production and consumption and storage; risks associated with any future vessel construction; our expectations regarding the availability of vessel acquisitions and our ability to complete acquisition transactions planned; availability of skilled crew members other employees and the related labor costs; work stoppages or other labor disruptions by our employees or the employees of other companies in related industries; effects of new products and new technology in our industry; new environmental regulations and restrictions; the impact of an interruption in or failure of our information technology and communications systems, including the impact of cyber-attacks, upon our ability to operate; potential conflicts of interest involving members of our Board of Directors and Senior Management; the failure of counterparties to fully perform their contracts with us; changes in credit risk with respect to our counterparties on contracts; adequacy of insurance coverage; our ability to obtain indemnities from customers; changes in laws, treaties or regulations; our incorporation under the laws of England and Wales and the different rights to relief that may be available compared to other countries, including the United States; government requisition of our vessels during a period of war or emergency; the arrest of our vessels by maritime claimants; any further changes in U.S. trade policy that could trigger retaliatory actions by the affected countries; the impact of the U.S. presidential and congressional election results affecting the economy, future government laws and regulations and trade policy matters, such as the imposition of tariffs and other import restrictions; potential disruption of shipping routes due to accidents, climate-related incidents, adverse weather and natural disasters, environmental factors, political events, public health threats, acts by terrorists or acts of piracy on ocean-going vessels; damage to storage and receiving facilities; potential liability from future litigation and potential costs due to environmental damage and vessel collisions; and the length and number of off-hire periods and dependence on third-party managers.

In the light of these risks and uncertainties, undue reliance should not be placed on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements.

Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Please see TORM's filings with the U.S. Securities and Exchange Commission for a more complete discussion of certain of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/torm-plc/r/torm-plc-upgrades-full-year-guidance,c4407660

The following files are available for download:

SOURCE Torm PLC

Share this article

RTX's Raytheon to advance target-detection capabilities for naval radars

Software‑driven upgrades to increase range and efficiency

PORTSMOUTH, R.I., Oct. 12, 2026 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, has been awarded a contract from the Office of Naval Research (ONR) to develop advanced target‑detection capabilities for naval radar systems.

Under the contract, Raytheon's Advanced Technology team will develop and evaluate advanced signal and data-processing algorithms and integrate targeted software upgrades to significantly extend detection range, increase sensitivity and improve radar-system efficiency. These enhancements will undergo rigorous laboratory and field testing to validate performance and operational use, preparing them for transition into Raytheon's SPY‑6 family of radars and other future naval radars.

"Modernizing fielded radar systems with software-first upgrades is one of the fastest and most cost-effective ways to deliver mission-ready capability," said Colin Whelan, president of Advanced Technology at Raytheon. "These enhancements will enable naval operators to detect smaller objects at greater distances and classify targets more quickly, providing the fleet with faster, more informed decision‑making."

The program continues Raytheon's extensive work in software-defined apertures and leverages knowledge gained from prior ONR initiatives, including ASPIRE and STORM, which established foundational hardware and software advancements for next-generation radar capability.

Work under this contract will be conducted at Raytheon facilities in Portsmouth, R.I., and Andover, Massachusetts, through 2031.

Raytheon is significantly expanding its engineering workforce to support critical military programs. Opportunities are available for emerging talent, experienced professionals, and veterans. Discover open roles on our website and apply today.

About Raytheon

Raytheon, an RTX business, is a leading provider of defense solutions to help the U.S. government, our allies and partners defend their national sovereignty and ensure their security. For more than 100 years, Raytheon has developed new technologies and enhanced existing capabilities in integrated air and missile defense, smart weapons, missiles, advanced sensors and radars, interceptors, space-based systems, hypersonics and missile defense across land, air, sea and space.

About RTX

With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact [email protected].

Distribution Statement A: Approved for public release, distribution is unlimited.

SOURCE RTX

Share this article